Konrad Obermann

TL;DR: SHI in the Philippines has been a success story so far and provides lessons for countries in a similar situation and there is a strong need to push for high quality care and improved physical access.

TL;DR: Current German market costs for the NOACs exceed a willingness-to-pay threshold of (hypothetical) 50000€/QALY in all treatment regimen, and from a German public health care insurance perspective current market costs are high in relation to the quality of life gained.

TL;DR: Analysis of the role of the Philippine NHI scheme in moving towards UHC, identifying potential avenues for improvement as well as indicating challenges and areas for further development shows three areas that are of key importance in developing further NHI: governance, governance, financial impact, and strategic purchasing.

TL;DR: It is found that the current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective and the willingness-to-pay threshold was lowest for 60 mg edoxaban compared to all direct oral anti-cancerants and for 30 mg edoxban compared to dabigatran and rivaroxaban.

TL;DR: Insight into the existing ways that the sites were working with respect to integrated care, their perceived difficulties and their plans for working towards improvement are provided to suggest that broadly-based prevention efforts, population health promotion and community involvement remain limited.